Seikagaku Corp
TSE:4548
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Seikagaku Corp
Cash Equivalents
Seikagaku Corp
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Seikagaku Corp
TSE:4548
|
Cash Equivalents
¥7.8B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash Equivalents
¥654.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash Equivalents
¥541.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash Equivalents
¥534.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash Equivalents
¥7.4B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-23%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cash Equivalents
¥254.3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
Seikagaku Corp
Glance View
Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 913 full-time employees. The company went IPO on 2004-03-23. The firm operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
See Also
What is Seikagaku Corp's Cash Equivalents?
Cash Equivalents
7.8B
JPY
Based on the financial report for Dec 31, 2025, Seikagaku Corp's Cash Equivalents amounts to 7.8B JPY.
What is Seikagaku Corp's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
4%
Over the last year, the Cash Equivalents growth was -47%. The average annual Cash Equivalents growth rates for Seikagaku Corp have been -29% over the past three years , -8% over the past five years , and 4% over the past ten years .
